The launch of Reddy-Lenalidomide has been announced by Dr Reddy’s Laboratories Ltd. on Thursday. This is a generic equivalent to Revlimid (lenalidomide) capsules, in the Canadian market following approval from Health Canada.
A press release from the city-based drug maker said Reddy-Lenalidomide, a cancer drug, is one of the first generic medications of its kind to launch in Canada.
“Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population,” Vinod Ramachandran, Vice President and General Manager, Dr. Reddy’s Laboratories Canada said.
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
